Page 383 - Programme book for The International Liver Congress 2015, EASL ILC 2015

SATURDAY, APRIL 25, 2015 07:30 – 08:30

Bayer HealthCare Pharmaceuticals Strauss 1

Three dimensions in the management of intermediate-stage HCC

Chair: INDUSTRY INFORMATION
Jordi Bruix, Spain

Welcome and introduction
Jordi Bruix, Spain

Dimension 1: Managing patients who are not suitable for TACE

Case study presentation
Luigi Bolondi, Italy

Case study evaluation – panel discussion
Jordi Bruix, Spain

Evaluating the evidence
Luigi Bolondi, Italy

Dimension 2: Managing patients who partially respond to TACE

Case study presentation
Jordi Bruix, Spain

Case study evaluation – panel discussion
Jordi Bruix, Spain

Evaluating the evidence
Jordi Bruix, Spain

Dimension 3: Managing patients who do not respond to TACE

Case study presentation
Peter Galle, Germany

Case study evaluation – panel discussion
Jordi Bruix, Spain

Evaluating the evidence
Peter Galle, Germany

Q&A and closing remarks
Jordi Bruix, Spain

Vienna, Austria • April 22–26, 2015 383